000			02160 a2200589 4500
005			20250517085731.0
264		0	_c20170213
008			201702s 0 0 eng d
022			_a1872-7980
024	7		_a10.1016/j.canlet.2016.03.038 _2doi
040			_aNLM _beng _cNLM
100	1		_aLiu, Jingjing
245	0	0	_aGATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. _h[electronic resource]
260			_bCancer letters _c06 2016
300			_a104-9 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAntineoplastic Agents, Hormonal _xadverse effects
650	0	4	_aBiomarkers, Tumor _xgenetics
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aChi-Square Distribution
650	0	4	_aDNA Mutational Analysis
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aGATA3 Transcription Factor _xgenetics
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHumans
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aLogistic Models
650	0	4	_aMultivariate Analysis
650	0	4	_aMutation
650	0	4	_aNeoplasm Recurrence, Local
650	0	4	_aOdds Ratio
650	0	4	_aProportional Hazards Models
650	0	4	_aRNA, Messenger _xgenetics
650	0	4	_aReceptors, Estrogen _xantagonists & inhibitors
650	0	4	_aRetrospective Studies
650	0	4	_aRisk Factors
650	0	4	_aSelective Estrogen Receptor Modulators _xadverse effects
650	0	4	_aTamoxifen _xadverse effects
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aPrager-van der Smissen, Wendy J C
700	1		_aLook, Maxime P
700	1		_aSieuwerts, Anieta M
700	1		_aSmid, Marcel
700	1		_aMeijer-van Gelder, Marion E
700	1		_aFoekens, John A
700	1		_aHollestelle, Antoinette
700	1		_aMartens, John W M
773	0		_tCancer letters _gvol. 376 _gno. 1 _gp. 104-9
856	4	0	_uhttps://doi.org/10.1016/j.canlet.2016.03.038 _zAvailable from publisher's website
999			_c25867350 _d25867350